FeesSafety
Pluang+

McEwen rated BUY with $31 target on copper growth and key project catalysts.

Company Fundamentals
05 Sep 2026
Seeking Alpha
View Source
Bullish
McEwen rated BUY with $31 target on copper growth and key project catalysts.

McEwen Inc. (MUX) is rated a BUY with a $31 price target, driven by expected long-term growth in assets and copper production. The company plans to increase production from 115,700 ounces in 2025 to up to 300,000 ounces by 2030 with minimal dilution. The Los Azules copper project, where McEwen holds a 46% stake plus royalties, offers significant upside potential not yet reflected in current stock prices. Near-term catalysts include the Gold Bar reconciliation, final investment decision on Los Azules, and the McEwen Copper IPO, though risks remain around execution and dilution.

More News

Chery launches Globalisation 3.0 strategy focusing on AI and green tech for future growth

Chery launches Globalisation 3.0 strategy focusing on AI and green tech for future growth

Chery unveiled its Globalisation 3.0 strategy at the 2026 International User Summit, aiming to transform from a traditional automaker into a high-tech integrated ecosystem by 2035. The strategy emphasizes AI adoption, green technologies, and local ma...

Market News
Bullish
3 hours ago
Intel's Q3 margin report on Oct 29 is crucial after shares fell 13% since July's strong results.

Intel's Q3 margin report on Oct 29 is crucial after shares fell 13% since July's strong results.

Intel will report its third-quarter results on October 29, with profit margins expected to be the key focus after shares dropped 13.24% since July. The last quarter showed record revenue and strong growth in data center and AI segments, but a large n...

Company Fundamentals
Neutral
4 hours ago
Merck's Q3 results on Oct 29 will reveal if new drugs can offset Keytruda's 2028 patent loss.

Merck's Q3 results on Oct 29 will reveal if new drugs can offset Keytruda's 2028 patent loss.

Merck will report its Q3 2026 results on October 29, with investors focused on whether new drug launches like LIPFENDRA, QLEX, and WINREVAIR can compensate for the expected loss of patent exclusivity for Keytruda in 2028. Last quarter, revenue grew 5...

Company Fundamentals
Neutral
4 hours ago
XRP price risks falling to $0.98 as large holders sell off 50 million tokens, threatening market support.

XRP price risks falling to $0.98 as large holders sell off 50 million tokens, threatening market support.

Twelve large XRP wallets have started distributing their holdings, causing a 50 million token influx on exchanges that threatens the price support established since August. This coordinated sell-off by whales reduces the number of wallets holding 10 ...

Market News
Bearish
4 hours ago
Caterpillar's $72B backlog may boost stock after 15% drop ahead of Q3 earnings on Oct 29.

Caterpillar's $72B backlog may boost stock after 15% drop ahead of Q3 earnings on Oct 29.

Caterpillar reports Q3 results on October 29 amid a 15.4% stock drop over the past month despite a record $72 billion backlog. Last quarter, the company posted $20.54 billion in revenue, a 24% increase year-over-year, and raised its 2026 sales growth...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App